| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Jeffrey K. Rhodes is Director at TPG. Jeffrey K. Rhodes's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $6.1M at current prices.
The TPG filings lean toward selling, a net 408,675 shares.
Jeffrey K. Rhodes has 21 Form 4 filings on record from March 2017 to August 2026, across 3 companies: Director at TPG Operating Group II, L.P. 6.950% Fixed-Rate Junior Subordinated Notes due 2064 (TPGXL), 2026; Director at TPG (TPG), 2024–2026; Director at Zimmer Biomet (ZBH), 2017–2018.
The 27 reported transactions were 17 option or other derivative awards, 3 tax withholdings, 3 stock awards and 2 gifts, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $17.0M.
The only open-market sale was 408,675 shares of TPG at an average $41.64 on February 29, 2024, about $17.0M. Twelve months later TPG was up 24%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 29, 2024 | TPG Tpg Inc. | Director | Sale+OE | 408,675 | $41.64 | $17,017,227.00 | -69.8% | -5.9% | +24.4% |